You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameS-Ethylisothiourea
Accession NumberDB02539  (EXPT02886)
TypeSmall Molecule
GroupsExperimental
DescriptionNot Available
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIINot Available
CAS number2986-20-1
WeightAverage: 104.174
Monoisotopic: 104.040818956
Chemical FormulaC3H8N2S
InChI KeyInChIKey=VFIZBHJTOHUOEK-UHFFFAOYSA-N
InChI
InChI=1S/C3H8N2S/c1-2-6-3(4)5/h2H2,1H3,(H3,4,5)
IUPAC Name
(ethylsulfanyl)methanimidamide
SMILES
CCSC(N)=N
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as isothioureas. These are organic compounds containing the isothiourea group, with the general structure R1SC(=NR2)N(R3)R4 (R1,R2,R3,R4=H, alkyl, aryl).
KingdomOrganic compounds
Super ClassOrganosulfur compounds
ClassIsothioureas
Sub ClassNot Available
Direct ParentIsothioureas
Alternative Parents
Substituents
  • Isothiourea
  • Sulfenyl compound
  • Carboximidamide
  • Thioether
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Imine
  • Aliphatic acyclic compound
Molecular FrameworkAliphatic acyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationNot Available
PharmacodynamicsNot Available
Mechanism of actionNot Available
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9417
Blood Brain Barrier+0.8566
Caco-2 permeable-0.6514
P-glycoprotein substrateNon-substrate0.7429
P-glycoprotein inhibitor INon-inhibitor0.9487
P-glycoprotein inhibitor IINon-inhibitor0.9516
Renal organic cation transporterNon-inhibitor0.8246
CYP450 2C9 substrateNon-substrate0.7953
CYP450 2D6 substrateNon-substrate0.7215
CYP450 3A4 substrateNon-substrate0.8339
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9494
CYP450 2D6 inhibitorInhibitor0.5903
CYP450 2C19 inhibitorNon-inhibitor0.9319
CYP450 3A4 inhibitorNon-inhibitor0.8807
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8695
Ames testNon AMES toxic0.9145
CarcinogenicityNon-carcinogens0.6958
BiodegradationNot ready biodegradable0.8293
Rat acute toxicity2.8731 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9836
hERG inhibition (predictor II)Non-inhibitor0.9611
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility4.77 mg/mLALOGPS
logP0.03ALOGPS
logP0.67ChemAxon
logS-1.3ALOGPS
pKa (Strongest Basic)10.59ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area49.87 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity39.78 m3·mol-1ChemAxon
Polarizability10.96 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with S-Ethylisothiourea.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with S-Ethylisothiourea.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with S-Ethylisothiourea.
adipiplonThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with S-Ethylisothiourea.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with S-Ethylisothiourea.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with S-Ethylisothiourea.
AmisulprideThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Amitriptyline.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with S-Ethylisothiourea.
AmoxapineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Amperozide.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with S-Ethylisothiourea.
ArticaineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Asenapine.
AzaperoneThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Azaperone.
AzelastineS-Ethylisothiourea may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with S-Ethylisothiourea.
BaclofenThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with S-Ethylisothiourea.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with S-Ethylisothiourea.
Benzyl alcoholThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Benzyl alcohol.
BrexpiprazoleThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of S-Ethylisothiourea.
BrimonidineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with S-Ethylisothiourea.
BrompheniramineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with S-Ethylisothiourea.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with S-Ethylisothiourea.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with S-Ethylisothiourea.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with S-Ethylisothiourea.
ButacaineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with S-Ethylisothiourea.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with S-Ethylisothiourea.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with S-Ethylisothiourea.
CarbinoxamineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with S-Ethylisothiourea.
CarisoprodolThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Carisoprodol.
CetirizineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with S-Ethylisothiourea.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with S-Ethylisothiourea.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with S-Ethylisothiourea.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with S-Ethylisothiourea.
ChlorphenamineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Chlorphenamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with S-Ethylisothiourea.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with S-Ethylisothiourea.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Chlorzoxazone.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with S-Ethylisothiourea.
CitalopramThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Citalopram.
ClemastineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with S-Ethylisothiourea.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with S-Ethylisothiourea.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with S-Ethylisothiourea.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with S-Ethylisothiourea.
CyclizineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with S-Ethylisothiourea.
CyproheptadineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Cyproheptadine.
DantroleneThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with S-Ethylisothiourea.
DapoxetineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Dapoxetine.
deramciclaneThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with S-Ethylisothiourea.
DesipramineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Detomidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with S-Ethylisothiourea.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with S-Ethylisothiourea.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with S-Ethylisothiourea.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with S-Ethylisothiourea.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with S-Ethylisothiourea.
DifenoxinThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with S-Ethylisothiourea.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with S-Ethylisothiourea.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with S-Ethylisothiourea.
DimenhydrinateThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with S-Ethylisothiourea.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with S-Ethylisothiourea.
DoramectinThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Doxepin.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of S-Ethylisothiourea.
DoxylamineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of S-Ethylisothiourea.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with S-Ethylisothiourea.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with S-Ethylisothiourea.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with S-Ethylisothiourea.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with S-Ethylisothiourea.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with ECGONINE METHYL ESTER.
EfavirenzThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Efavirenz.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with S-Ethylisothiourea.
EntacaponeThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Entacapone.
EscitalopramThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Escitalopram.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with S-Ethylisothiourea.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with S-Ethylisothiourea.
EthanolS-Ethylisothiourea may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with S-Ethylisothiourea.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with S-Ethylisothiourea.
EthosuximideThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with S-Ethylisothiourea.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with S-Ethylisothiourea.
EtidocaineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with S-Ethylisothiourea.
EtoperidoneThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with S-Ethylisothiourea.
EzogabineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with S-Ethylisothiourea.
FenfluramineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with S-Ethylisothiourea.
FexofenadineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with S-Ethylisothiourea.
FlunarizineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with S-Ethylisothiourea.
FluoxetineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with S-Ethylisothiourea.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with S-Ethylisothiourea.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with S-Ethylisothiourea.
FluspirileneThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Fluvoxamine.
FosphenytoinThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Fospropofol.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with S-Ethylisothiourea.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with S-Ethylisothiourea.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with S-Ethylisothiourea.
GuanfacineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with S-Ethylisothiourea.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with S-Ethylisothiourea.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with S-Ethylisothiourea.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with S-Ethylisothiourea.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with S-Ethylisothiourea.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with S-Ethylisothiourea.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with S-Ethylisothiourea.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of S-Ethylisothiourea.
HydroxyzineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Hydroxyzine.
IloperidoneThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Iloperidone.
ImipramineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Indalpine.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with S-Ethylisothiourea.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with S-Ethylisothiourea.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with S-Ethylisothiourea.
KetobemidoneThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Ketobemidone.
LamotrigineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with S-Ethylisothiourea.
LevocabastineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with S-Ethylisothiourea.
LevomilnacipranThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with S-Ethylisothiourea.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with S-Ethylisothiourea.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with S-Ethylisothiourea.
LofentanilThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Lofentanil.
LoratadineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with S-Ethylisothiourea.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with S-Ethylisothiourea.
Lu AA21004The risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Lu AA21004.
LurasidoneThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of S-Ethylisothiourea.
Magnesium SulfateThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with S-Ethylisothiourea.
MelperoneThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Melperone.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with S-Ethylisothiourea.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with S-Ethylisothiourea.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with S-Ethylisothiourea.
MetaxaloneThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with S-Ethylisothiourea.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with S-Ethylisothiourea.
MethapyrileneThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with S-Ethylisothiourea.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with S-Ethylisothiourea.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with S-Ethylisothiourea.
MethsuximideThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with S-Ethylisothiourea.
MetyrosineS-Ethylisothiourea may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with S-Ethylisothiourea.
MilnacipranThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of S-Ethylisothiourea.
MirtazapineS-Ethylisothiourea may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with S-Ethylisothiourea.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with S-Ethylisothiourea.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with S-Ethylisothiourea.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of S-Ethylisothiourea.
NabiloneThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Nabilone.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with S-Ethylisothiourea.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with S-Ethylisothiourea.
Nitrous oxideThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Olanzapine.
OlopatadineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with S-Ethylisothiourea.
OpiumThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Opium.
OrphenadrineS-Ethylisothiourea may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with S-Ethylisothiourea.
OsanetantThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Osanetant.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with S-Ethylisothiourea.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with S-Ethylisothiourea.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with S-Ethylisothiourea.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with S-Ethylisothiourea.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with S-Ethylisothiourea.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with S-Ethylisothiourea.
ParaldehydeS-Ethylisothiourea may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with S-Ethylisothiourea.
ParoxetineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Paroxetine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with S-Ethylisothiourea.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with S-Ethylisothiourea.
PerampanelThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with S-Ethylisothiourea.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with S-Ethylisothiourea.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with S-Ethylisothiourea.
PhenoxyethanolThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Phenoxyethanol.
PhenytoinThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with S-Ethylisothiourea.
PipamperoneThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Pomalidomide.
PramipexoleS-Ethylisothiourea may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with S-Ethylisothiourea.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with S-Ethylisothiourea.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with S-Ethylisothiourea.
PrimidoneThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with S-Ethylisothiourea.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with S-Ethylisothiourea.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with S-Ethylisothiourea.
PromethazineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with S-Ethylisothiourea.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with S-Ethylisothiourea.
PropoxycaineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with S-Ethylisothiourea.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with S-Ethylisothiourea.
RamelteonThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Ramelteon.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with S-Ethylisothiourea.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with S-Ethylisothiourea.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with S-Ethylisothiourea.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with S-Ethylisothiourea.
RomifidineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Romifidine.
RopiniroleS-Ethylisothiourea may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with S-Ethylisothiourea.
RotigotineS-Ethylisothiourea may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with S-Ethylisothiourea.
ScopolamineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with S-Ethylisothiourea.
SertindoleThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with S-Ethylisothiourea.
Sodium oxybateThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Sodium oxybate.
StiripentolThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with S-Ethylisothiourea.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with S-Ethylisothiourea.
SuvorexantThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Tasimelteon.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with S-Ethylisothiourea.
TetrabenazineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Tetrodotoxin.
ThalidomideS-Ethylisothiourea may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with S-Ethylisothiourea.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with S-Ethylisothiourea.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with S-Ethylisothiourea.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with S-Ethylisothiourea.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with S-Ethylisothiourea.
TiagabineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Tiagabine.
TiletamineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Tiletamine.
TizanidineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Tizanidine.
TolcaponeThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Tolcapone.
TopiramateThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with S-Ethylisothiourea.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with S-Ethylisothiourea.
TrazodoneThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with S-Ethylisothiourea.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with S-Ethylisothiourea.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with S-Ethylisothiourea.
TrimipramineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Triprolidine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with S-Ethylisothiourea.
VigabatrinThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Vilazodone.
VortioxetineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with S-Ethylisothiourea.
ZiconotideThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with S-Ethylisothiourea.
ZolazepamThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with S-Ethylisothiourea.
ZonisamideThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with S-Ethylisothiourea.
ZotepineThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with S-Ethylisothiourea.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Tetrahydrobiopterin binding
Specific Function:
Produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body. In macrophages, NO mediates tumoricidal and bactericidal actions. Also has nitrosylase activity and mediates cysteine S-nitrosylation of cytoplasmic target proteins such COX2. As component of the iNOS-S100A8/9 transnitrosylase complex involved in the selective inflammatory stimulus-dependent S-n...
Gene Name:
NOS2
Uniprot ID:
P35228
Molecular Weight:
131116.3 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23